Models to Know: Fogg Behavior Model

Models to Know: Fogg Behavior Model

Today I want to share the most powerful and useful model of behavior that I’ve ever encountered: The Fogg Behavior Model. There have been few other ideas that have impacted the way I think and see the world as much as this simple, yet devilishly useful, model.


The Fogg Behavior Model states that three things need to come together in order for a behavior to occur:

  • Motivation
  • Ability
  • Trigger (a cue)
  • If an ample degree of motivation to perform a behavior is matched with the ability to do that behavior, all that is then needed for the behavior to occur is a reminder or call-to-action (a trigger).

    Anytime you want to better understand why a behavior isn’t occurring, all you have to do is simply walk down the list and ask:

  • Are they amply motivated?
  • Are they truly able to perform this behavior?
  • Are we just forgetting to remind them/ask them to perform the behavior?
  • Often, the problem is obvious at this point. But, sometimes, you need to dig a bit deeper into each of the different elements, especially ability.

    To do this, BJ created what he calls the “Six Elements of Simplicity” (or Ability):

  • Time
  • Money
  • Physical Effort
  • Brain Cycles (Mental Effort)
  • Social Deviance
  • Non-Routine
  • You can look at each of these elements as ability blockers – things that reduce one’s ability. 

    Time: You have more ability to perform a behavior that takes very little time versus one that takes a lot of time.

    Money: You have more ability to perform a behavior that costs very little money versus one that costs a lot of money.

    Physical Effort: You have more ability to perform a behavior that requires little physical effort and strain versus one that requires a lot of physical effort and strain.

    Mental Cycles: You have more ability to perform a behavior that is not mentally fatiguing or challenging versus one that is.

    Social Deviance: You have more ability to perform a behavior that is socially acceptable versus one that isn’t.

    Non-Routine: Your ability to perform a given behavior will change over time, and will have a greater ability to perform behaviors that are routine (versus behaviors that are non-routine).

    The goal with each of these “Elements of Simplicity” is to minimize them as much as possible. You want to design quick and physically/mentally easy behaviors that don’t cost a lot of money or violate any social norms. This is easier said than done.

    Before you go down this path of optimizing ability and motivation, however, I recommend that you do something very simple: make sure that you’re triggering the behaviors you want to occur. We live extremely busy and hectic lives and are in habit-mode most of the time. If we want to break out of our habitual machinations and do something new, we need to be reminded. This is why triggers are so important. They can be as simple as text messages, emails, or post it notes (or as complicated as a visit from a life coach or personal trainer).

    If you trigger yourself properly, make sure that your behaviors are as simple as possible, and make sure that you’re doing something you really care about (motivation), the path towards behavior induction will be simple. If you don’t follow these things… well that’s a story for another article.

    U.S. Navy controls inventions that claim to change "fabric of reality"

    Inventions with revolutionary potential made by a mysterious aerospace engineer for the U.S. Navy come to light.

    U.S. Navy ships

    Credit: Getty Images
    Surprising Science
    • U.S. Navy holds patents for enigmatic inventions by aerospace engineer Dr. Salvatore Pais.
    • Pais came up with technology that can "engineer" reality, devising an ultrafast craft, a fusion reactor, and more.
    • While mostly theoretical at this point, the inventions could transform energy, space, and military sectors.
    Keep reading Show less

    Why so gassy? Mysterious methane detected on Saturn’s moon

    Scientists do not know what is causing the overabundance of the gas.

    An impression of NASA's Cassini spacecraft flying through a water plume on the surface of Saturn's moon Enceladus.

    Credit: NASA
    Surprising Science
    • A new study looked to understand the source of methane on Saturn's moon Enceladus.
    • The scientists used computer models with data from the Cassini spacecraft.
    • The explanation could lie in alien organisms or non-biological processes.
    Keep reading Show less

    CRISPR therapy cures first genetic disorder inside the body

    It marks a breakthrough in using gene editing to treat diseases.

    Credit: National Cancer Institute via Unsplash
    Technology & Innovation

    This article was originally published by our sister site, Freethink.

    For the first time, researchers appear to have effectively treated a genetic disorder by directly injecting a CRISPR therapy into patients' bloodstreams — overcoming one of the biggest hurdles to curing diseases with the gene editing technology.

    The therapy appears to be astonishingly effective, editing nearly every cell in the liver to stop a disease-causing mutation.

    The challenge: CRISPR gives us the ability to correct genetic mutations, and given that such mutations are responsible for more than 6,000 human diseases, the tech has the potential to dramatically improve human health.

    One way to use CRISPR to treat diseases is to remove affected cells from a patient, edit out the mutation in the lab, and place the cells back in the body to replicate — that's how one team functionally cured people with the blood disorder sickle cell anemia, editing and then infusing bone marrow cells.

    Bone marrow is a special case, though, and many mutations cause disease in organs that are harder to fix.

    Another option is to insert the CRISPR system itself into the body so that it can make edits directly in the affected organs (that's only been attempted once, in an ongoing study in which people had a CRISPR therapy injected into their eyes to treat a rare vision disorder).

    Injecting a CRISPR therapy right into the bloodstream has been a problem, though, because the therapy has to find the right cells to edit. An inherited mutation will be in the DNA of every cell of your body, but if it only causes disease in the liver, you don't want your therapy being used up in the pancreas or kidneys.

    A new CRISPR therapy: Now, researchers from Intellia Therapeutics and Regeneron Pharmaceuticals have demonstrated for the first time that a CRISPR therapy delivered into the bloodstream can travel to desired tissues to make edits.

    We can overcome one of the biggest challenges with applying CRISPR clinically.

    —JENNIFER DOUDNA

    "This is a major milestone for patients," Jennifer Doudna, co-developer of CRISPR, who wasn't involved in the trial, told NPR.

    "While these are early data, they show us that we can overcome one of the biggest challenges with applying CRISPR clinically so far, which is being able to deliver it systemically and get it to the right place," she continued.

    What they did: During a phase 1 clinical trial, Intellia researchers injected a CRISPR therapy dubbed NTLA-2001 into the bloodstreams of six people with a rare, potentially fatal genetic disorder called transthyretin amyloidosis.

    The livers of people with transthyretin amyloidosis produce a destructive protein, and the CRISPR therapy was designed to target the gene that makes the protein and halt its production. After just one injection of NTLA-2001, the three patients given a higher dose saw their levels of the protein drop by 80% to 96%.

    A better option: The CRISPR therapy produced only mild adverse effects and did lower the protein levels, but we don't know yet if the effect will be permanent. It'll also be a few months before we know if the therapy can alleviate the symptoms of transthyretin amyloidosis.

    This is a wonderful day for the future of gene-editing as a medicine.

    —FYODOR URNOV

    If everything goes as hoped, though, NTLA-2001 could one day offer a better treatment option for transthyretin amyloidosis than a currently approved medication, patisiran, which only reduces toxic protein levels by 81% and must be injected regularly.

    Looking ahead: Even more exciting than NTLA-2001's potential impact on transthyretin amyloidosis, though, is the knowledge that we may be able to use CRISPR injections to treat other genetic disorders that are difficult to target directly, such as heart or brain diseases.

    "This is a wonderful day for the future of gene-editing as a medicine," Fyodor Urnov, a UC Berkeley professor of genetics, who wasn't involved in the trial, told NPR. "We as a species are watching this remarkable new show called: our gene-edited future."

    Quantcast